Gut microbiome study in 3 healthy volunteers (ProDigest: SHIME system) Results

An invitro study in a simulated gut confirming the Arrive, Survive, Thrive of the bacteria in Symprove and providing insights into their role and effect in the gut microbiome.

Arrive & Survive

  • Our data show that the live bacteria contained within our unique Symprove® formulation
  • arrived in a live and active state – delivering 100% of the claimed dose
  • survived a 45-minute passage through the stomach
  • survived a 3-hour passage through the upper intestinal tract and repeated harsh environmental changes including bile salts and pancreatic fluids.

Thrive – Colonisation

All four of Symprove’s bacteria entered the large intestine in a live and metabolically active state.

The symprove bacteria successfully competed with the existing microbiome and rapidly colonized the colon and its lining in a species-specific manner.

By colonising the lining – the Symprove bacteria have a chance to facilitate the microbiome Interacting with the immune system.

By colonising the contents of the colon (lumen) – the symprove bacteria are able to influence the microbiome fermentation and overall balance of bacteria.

Thrive – Feeding the microbiome

The SymproveTM bacteria increased the production of lactate. This is an important substrate that feeds other bacteria species. Through this, it was demonstrated that

There was a significantly higher total Short Chain Fatty Acid (SCFA) production. These are important for general gut health. Of significant importance is increased Butyrate.

SymproveTM did not stimulate the production of the health-inhibiting ammonia and branched chain fatty acids, was not stimulated.

Drive – re-balance the microbiome

The bacteria in SymproveTM established colonies in an already stable and competitive environment in the three microbiomes, both lining and contents. Importantly, they did not outcompete the background microbiome.

They fed the existing microbiome, altering the bacterial diversity of the existing microbiota.

In the human microbiome, there are groups of bacteria that are may be considered beneficial and groups that are potentially negative to health and potetnially pathogenic.

There was an increased abundance of 2 key beneficial groups (Firmicutes and Actinobacteria), and a decrease in the negative groups (Proteobacteria and Bacterioidetes).

Drive – Activation of an Immunomodulatory Effect

The successful colonisation and re-balancing of the gut-microbiome enabled the host microbiome to have a positive Immunomodulatory effect.

Anti-Inflammatory substances were increased, (cytokines IL-6 and IL-10).
Inflammatory substances were reduced, (chemokines IL-8, MCP-1, CXCL10).
The intestinal wall integrity was maintained. (with no change to TEER, NF-κβ activation or IL- 1β secretion).


The addition of Symprove to the SHIME system from healthy volunteer donors shows that an uncompromised healthy biome may be modified by:-

  1. Arrival and survival of probiotic bacteria through the stomach acid and gastric fluids
  2. Successful colonisation of all bacteria and the production of lactate
  3. Nourishing other bacteria in the biome to produce substrates that may impact health – beneficial substances, including increased Butyrate levels, and reducing harmful fermentation.
  4. An increased abundance of the beneficial bacteria groups whereas the harmful bacteria groups were decreased.

These results were based on microbiomes of three healthy donors

Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), consisting of 5 sequential reactors, which simulate the different regions of the human intestinal tract, providing a continuous model for long term administration studies.

Fecal samples from three healthy adult donors were tested separately in the SHIME gut models. Symprove was dosed daily for three weeks following a four-week stabilization and control period. The SHIME exposes the Symprove to gastric acid and intestinal fluids. The effect of Symprove on the microbiome on bacterial metabolites, gut permeability and immune markers was assessed.